Phase 3 N=8 Vaping THC From Electronic Cigarettes
Marijuana Dependence
Primary: Mean Delivered and Retained Doses — 0.016; 0.018; 0.026 grams (g)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=101 Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Triple-negative Breast Cancer
Primary: Number of Participants With Pathological Complete Response — 26; 28 Participants
Phase 3 N=637 Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority…
Phase 3 N=1,388 Preoperative CHG Cloth on Healthy Subjects
Surgery
Primary: Percent Responder Rates of Bacterial Reduction on the Abdomen and Groin Sites — 80; 75; 86; 65 % of Treated Sites
N/A N=7,308 Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics
Arthritis, Rheumatoid
Primary: Number of Participants Who Were on Combination Therapy and Monotherapy During 90 Days After Index Date — 183; 168; 2001; 119 Participants
Phase 2 N=18 Anakinra for Inflammatory Pustular Skin Diseases
Sneddon-Wilkinson · Acrodermatitis Continua of Hallopeau · Pustular Psoriasis
Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…
Phase 3 N=637 Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Multiple Myeloma
Primary: Progression-Free Survival (PFS) — 7.63; 6.83 Months — p== 0.0100
Phase 2 N=196 Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
Skin Diseases, Bacterial · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment Visit (ITT Population) — 102; 51; 3; 6 Participants
Phase 2 N=106 Safety and Efficacy of C21 in Subjects With COVID-19
COVID-19
Primary: Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.) — 0.19; 0.22 mg/L — p==0.4891
N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
Phase 3 N=3,086 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
Cholera
Primary: Seroconversion Rate at Day 11 — 90.4; 93.5 % of participants
N/A N=20 Feasibility of mindBEAGLE in Disorders of Consciousness or Locked-In Syndrome
Consciousness Disorders · Locked-In Syndrome
Primary: Behavioral Diagnosis of Level of Consciousness (LoC) — 0; 23; 2; 23 score on a scale
Phase 1 N=15 A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 12; 2 Participants
Early Phase 1 N=49 Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers
Cigarette Smoking-Related Carcinoma · Tobacco-Related Carcinoma
Primary: Change in Urinary Excretion of the Mercapturic Acid of Benzene Following 4 Tablets Per Day of Avmacol — 1.16 data presented as ratio; no unit
Phase 2 N=771 To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 Months — -0.004; -0.023; -0.018; -0.035 Liters